Everett Harris & Co. CA Makes New $11.25 Million Investment in Waters Corporation $WAT

Key Points

• Everett Harris & Co. CA purchased 29,991 Waters shares worth approximately $11.25 million during the second quarter. Institutional investors collectively own 94.01% of the company.
• Waters reported quarterly EPS of $3.05, exceeding estimates of $3.01, while revenue reached $1.65 billion and rose 113.3% year over year. The company guided for fiscal 2026 EPS of $14.45–$14.65.
• Analyst sentiment remains positive, with a consensus “Moderate Buy” rating and an average price target of $420.35; recent targets range as high as $475, although one analyst downgraded the stock to “hold.”

Everett Harris & Co. CA bought a new position in shares of Waters Corporation (NYSE:WAT - Free Report) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 29,991 shares of the medical instruments supplier's stock, valued at approximately $11,248,000.

Several other institutional investors have also recently made changes to their positions in WAT. Anchor Investment Management LLC bought a new stake in shares of Waters during the first quarter valued at approximately $27,000. Resources Management Corp CT ADV bought a new position in Waters in the first quarter worth $27,000. Zions Bancorporation National Association UT lifted its position in Waters by 121.2% during the fourth quarter. Zions Bancorporation National Association UT now owns 73 shares of the medical instruments supplier's stock valued at $28,000 after buying an additional 40 shares during the period. Vision Retirement LLC purchased a new position in Waters during the first quarter valued at $29,000. Finally, Bollard Group LLC bought a new stake in shares of Waters during the 1st quarter valued at $29,000. Institutional investors own 94.01% of the company's stock.

Waters Stock Performance

Shares of WAT stock opened at $411.88 on Friday. The company has a market capitalization of $40.47 billion, a price-to-earnings ratio of 102.71, a price-to-earnings-growth ratio of 2.40 and a beta of 1.19. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.50 and a current ratio of 1.86. Waters Corporation has a one year low of $282.77 and a one year high of $420.26. The company's 50-day moving average is $377.18 and its 200 day moving average is $346.31.

Waters (NYSE:WAT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $3.05 earnings per share for the quarter, topping analysts' consensus estimates of $3.01 by $0.04. Waters had a net margin of 3.58% and a return on equity of 11.27%. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.62 billion. During the same period in the previous year, the business earned $2.95 EPS. The firm's revenue for the quarter was up 113.3% on a year-over-year basis. Waters has set its Q3 2026 guidance at 3.950-4.050 EPS and its FY 2026 guidance at 14.450-14.650 EPS. Sell-side analysts expect that Waters Corporation will post 14.57 EPS for the current fiscal year.

Analyst Ratings Changes

WAT has been the subject of several research reports. HSBC increased their price target on shares of Waters from $415.00 to $435.00 and gave the stock a "buy" rating in a research note on Wednesday, June 3rd. Royal Bank Of Canada boosted their price objective on shares of Waters from $435.00 to $475.00 and gave the stock an "outperform" rating in a research note on Wednesday, August 5th. Wall Street Zen cut shares of Waters from a "buy" rating to a "hold" rating in a report on Monday, July 20th. Bank of America lifted their target price on shares of Waters from $370.00 to $400.00 and gave the company a "neutral" rating in a report on Tuesday, June 2nd. Finally, Barclays boosted their price target on Waters from $425.00 to $460.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and eight have issued a Hold rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $420.35.

Insider Buying and Selling at Waters

In other news, Director Christopher A. Kuebler sold 3,626 shares of the business's stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $397.94, for a total value of $1,442,930.44. Following the completion of the transaction, the director owned 17,808 shares in the company, valued at $7,086,515.52. The trade was a 16.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.31% of the stock is owned by corporate insiders.

Waters Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.

Want to see what other hedge funds are holding WAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Waters Corporation (NYSE:WAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source